Technology

Our modular proteins and antibodies are uniquely designed to address specific disease mechanisms and ensure manufacturability at the outset.

We use a combination of functional screening and structural modeling to advance candidates with the right biological properties and manufacturability.

 

By bringing deep insights into the complex mechanisms underlying the immune pathways we wish to modulate, the Pandion team can exploit customized primary cell assays to our advantage and identify new biomarkers that accurately reflect the pharmacodynamic effects of our therapeutics.

For the effector component of the therapeutics we consider the impact of valency on eliciting agonism by receptor clustering. We also consider the impact of geometry on function of geometry or spatial constraints imposed by effector moiety format (Fab vs scFv), domain placement, and isotype. For the tether component of the molecule, functional screens play an important role in ensuring no unwanted biology arises as a result of tether target engagement. Early bispecific leads undergo configuration scanning to evaluate different component placements, format, and linker configurations.

Manufacturability assessments are conducted at each stage of the discovery process to ensure only the most robust components advance in the screening cascade. This helps us understand and mitigate risks before our molecules progress into CMC. Special emphasis is placed on generating modular proteins with highly desirable drug-like properties for each effector and tissue tether pair to ensure a seamless transition from drug discovery into drug development.

Back to Top